WESTLAKE VILLAGE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc . (Nasdaq: KYTH ) today announced it will release its first quarter 2015 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, May 7, 2015.
Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number 28863520. To access the webcast, please visit the Investors section of KYTHERA's website at www.kythera.com .
The call will be available for replay via telephone starting May 7, 2015, at approximately 5:30 p.m. ET, running through 11:59 p.m. ET on May 13, 2015. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 28863520. The archived webcast will be available on KYTHERA's website for seven days beginning approximately one hour after the call has completed.
About KYTHERA ®
KYTHERA Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Its lead product, KYBELLA™ (deoxycholic acid) is the first and only approved injectable drug for contouring moderate to severe submental fullness, a condition that is commonly referred to as a double chin. KYTHERA also licensed the worldwide rights to setipiprant (KYTH-105), an early-stage potential treatment for hair loss. KYTHERA's longer-term strategy is to leverage its biotechnology and aesthetics experience to expand its product portfolio and pipeline. KYTHERA has submitted regulatory filings for ATX-101 in Canada, Switzerland and Australia. Find more information at www.kythera.com .
Investor Contact: Heather Rowe, Director, Investor Relations Tel: (818) 587- 4559